Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OLMA 
Olema Pharmaceuticals Inc (OLMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OLMA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 9.68% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 280.85M USD | Price to earnings Ratio - | 1Y Target Price 25.71 |
Price to earnings Ratio - | 1Y Target Price 25.71 | ||
Volume (30-day avg) 921333 | Beta 2.12 | 52 Weeks Range 3.28 - 16.62 | Updated Date 04/1/2025 |
52 Weeks Range 3.28 - 16.62 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.01 |
Earnings Date
Report Date 2025-03-10 | When Before Market | Estimate 0.1732 | Actual -0.51 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.43% | Return on Equity (TTM) -39.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -175724676 | Price to Sales(TTM) - |
Enterprise Value -175724676 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.33 | Shares Outstanding 68333104 | Shares Floating 41105755 |
Shares Outstanding 68333104 | Shares Floating 41105755 | ||
Percent Insiders 3.21 | Percent Institutions 101.72 |
Analyst Ratings
Rating 4.62 | Target Price 28 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Olema Pharmaceuticals Inc
Company Overview
History and Background
Olema Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers. It was founded in 2019 and went public in 2021. The company's initial focus is on developing therapies that address unmet needs in estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Core Business Areas
- Drug Development: Researching, developing, and testing novel therapies for cancer treatment, primarily focused on ER+/HER2- breast cancer.
Leadership and Structure
Sean P. Bohen, M.D., Ph.D., serves as the President and Chief Executive Officer. The company has a typical biotech structure with departments focused on research, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Palazestrant (OP-1250): Palazestrant is Olema's lead product candidate, an oral Selective Estrogen Receptor (SERD) for the treatment of ER+/HER2- breast cancer. It's currently in clinical trials. Revenue is currently $0 as it is still undergoing clinical trials. Competitors include SERDs such as elacestrant (Orserdu) from Menarini and AstraZeneca's fulvestrant (Faslodex), as well as CDK4/6 inhibitors.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly oncology, is highly competitive and research-intensive. The market for breast cancer therapies is substantial and growing.
Positioning
Olema aims to differentiate its SERD with improved efficacy and tolerability compared to existing treatments. It is positioned as a potential best-in-class oral SERD.
Total Addressable Market (TAM)
The global breast cancer therapeutics market is projected to reach hundreds of billions USD. Olema aims to capture a significant share of the ER+/HER2- segment, estimated in the tens of billions. They are positioned to enter the market and potentially replace older treatments with their new SERD.
Upturn SWOT Analysis
Strengths
- Novel SERD with potential for improved efficacy
- Experienced management team
- Strong intellectual property position
- Focused on a large and underserved market
Weaknesses
- Early-stage clinical development (high risk)
- Reliance on a single lead product candidate
- Limited financial resources compared to larger pharmaceutical companies
- No approved products generating revenue
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other cancer indications
- Acquisition by a larger company
Threats
- Clinical trial failures
- Competition from existing and emerging therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- AZN
- SNY
Competitive Landscape
Olema faces competition from established pharmaceutical companies with approved breast cancer therapies and other biotechs developing novel treatments. Its advantage lies in the potential for Palazestrant to offer superior efficacy and tolerability. Its disadvantage is lack of current product offerings and revenue.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Since its founding in 2019, Olema has rapidly advanced its lead product candidate, Palazestrant, through preclinical and early clinical development.
Future Projections: Future growth hinges on the successful completion of clinical trials and potential commercialization of Palazestrant. Analyst estimates vary but generally project significant revenue growth if Palazestrant is approved.
Recent Initiatives: Initiated and continued clinical trials for Palazestrant in various breast cancer settings.
Summary
Olema Pharmaceuticals is a relatively young biopharmaceutical company focused on developing novel therapies for women's cancers. Its lead product, Palazestrant, shows promise as a next-generation SERD for ER+/HER2- breast cancer. The company's success hinges on the positive outcome of ongoing clinical trials. Key risks include clinical trial failures and competition from larger pharmaceutical companies. Olema needs to prove their product can become a viable option for patients and medical professionals.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Olema Pharmaceuticals Inc. SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Olema Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2020-11-19 | President, CEO & Director Dr. Sean P. Bohen M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 96 | Website https://olema.com |
Full time employees 96 | Website https://olema.com | ||
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.